Benefit-Risk Profile of Upadacitinib: Exploratory Post Hoc Analysis of Phase 2b/3 Studies in Patients With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease.

Fiche publication

Date publication

novembre 2025

Journal

Journal of Crohn's & colitis

Auteurs

Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent

Tous les auteurs :
Vermeire S, Colombel JF, Danese S, Panaccione R, Peyrin-Biroulet L, Beck K, Chaparro M, Gisbert JP, Dubcenco E, Klaff J, Naling G, Ford S, Remple V, Joshi N, Suravaram S, Duncan B, Wang Y, Wick-Urban B, Loftus EV

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/41264726

Résumé

Upadacitinib (UPA)-an oral, reversible selective Janus kinase inhibitor-has a favorable benefit-risk profile for patients with Crohn's disease (CD) and ulcerative colitis (UC). We evaluated the benefit-risk of UPA in select subgroups with CD or UC.